Is HSBC Holdings an Exciting Emerging Market Play?

LONDON: Crippling austerity in Europe, and the prospect of fresh fiscal obstacles in the U.S. could put the brakes on growth rates in these regions. However, in developing geographies, a backdrop of accommodative central bank action, elevated commodity prices, and rising personal affluence levels have created an environment of exceptional commercial opportunity.

The divergence between the growth prospects of traditional and emerging markets is borne out by the International Monetary Fund's (IMF) latest growth projections, which expects developing nations and emerging markets to expand 5.3% and 5.7% in 2013 and 2014, respectively. By comparison, it anticipates that the U.S. economy will rise just 1.9% this year, and 3% in 2014, while eurozone GDP is forecast to dip 0.3% in 2013 before rebounding just 1.1% next year.

Bubbly activity in new geographies can create lucrative openings for many London-listed firms. Today, I'm looking at HSBC Holdings  (LSE: HSBA  ) (NYSE: HBC  )  and assessing whether their operations in these regions are likely to underpin solid earnings growth.

Asia-Pacific activity surges in 2012
Continued weakness in the bombed-out economies of Europe shoved groupwide pre-tax profit 6% lower, to $20.6bn last year, HSBC announced in March.

However, profits from key developing regions strode higher during the 12-month period. Profit before tax from Hong Kong rose 30% last year, to $7.6bn, while the rest of the Asia-Pacific territory recorded 40% profit growth to $10.4bn.

Combined, the whole Asia-Pacific region now accounts for almost nine-tenths of group profit, compared with around 60% in 2011. Meanwhile, activities in Latin America yielded pre-tax profits of $2.6bn, a 3% annual increase, although in the Middle East and North Africa, profit fell 10%, to $1.4bn.

But this pales in comparison to insipid performance in Europe, where operations slumped to a loss of $3.4bn in 2012 from profit of $4.7bn the previous year. Profit in North America also surged, to $2.3bn in 2012 from $100m, although this was due, in large part, to lower impairment charges.

HSBC expects surging economic growth in China to boost activity in 2013, as well as providing a shot in the arm from neighbouring countries, while it also anticipates growth in Latin America to gain traction as regional keystone Brazil picks up the pace. Although it expects the U.S. economic recovery to continue tentatively this year, political, economic, and regulatory woes in Europe are likely to weigh on operations there.

And recent data from the bank's divisions point to a continuation in its developing market growth story. Subsidiary The Saudi British Bank announced in mid-April that net profit rose 11%, to $253m in the first quarter. Customer deposits rose 9.4%, to $32.6bn, while loans and advances increased 11% to $27bn. Meanwhile, the bank's investment portfolio grew a massive 37.4%, to $8.6bn.

So is HSBC Holdings a buy?
Rocketing activity in emerging markets is expected to significantly boost revenues in coming years, and City analysts expect earnings-per-share growth of 31% and 12% in 2013 and 2014, respectively, to 64p and 71p. And a P/E reading of 10.9 and 9.8 for these years represents excellent value when viewed against a prospective earnings multiple of 12.7 for the whole banking sector.

Allied with an ultra-generous dividend policy -- brokers expect payouts of 33p in 2013, and 36.9p in 2014 to carry yields of 4.9% and 5.4%, respectively -- I believe that HSBC is a stunning stock market pick.

Bolster your investment income with the Fool
If you already hold shares in HSBC Holdings, and are looking for more FTSE 100 winners to really jump start your investment income, then you should check out this brand new and exclusive report covering a multitude of other premium payers right now.

Our "5 Dividend Winners To Retire On" wealth report highlights a selection of tasty stocks with an excellent record of providing juicy shareholder returns. Among our picks are top retail, pharmaceutical and utilities plays which we are convinced should continue to provide red-hot dividends. Click here to download the report -- it's 100% free and comes with no obligation.

3 Considerations in Deciding When to Take Social Security

One of the biggest decisions you'll face as you near retirement is when to start collecting Social Security. It's important to understand your options and the effect they can have on your retirement. Let's first address some of the basics of Social Security. Then we'll get into the specific considerations you must face in deciding when to start reaping your benefits.

A few basics
With Social Security making up roughly 40% of an average retiree's income, it's important for you to make a smart decision as to when you start collecting your benefit. Your choice is a personal, complex one that only you can make.

But there are several generalities about Social Security benefits. For example, monthly benefits are based on your highest 35 years of earnings (adjusted for inflation) and the age you start collecting benefits. The more money you made in your working years and the longer you delay taking Social Security, the higher your benefit.

Benefits are reduced by up to 25% if you claim at age 62, as opposed to your full retirement age. Meanwhile, benefits are increased by up to 32% -- roughly 8% per year -- if you delay taking benefits until age 70.

A big decision
Carefully examine these three factors to help you determine when you should start collecting your benefit.

1. Life expectancy
Most consideration around Social Security hinges on a breakeven date. That refers to the date when individuals who wait to collect larger benefits overtake those who took smaller benefits early. For most folks, that date falls somewhere in your late 70s or early 80s.

If longevity isn't in your genes, your life expectancy may not exceed your breakeven date. In that case, collecting benefits early could give you more money than waiting for larger benefits that you'll potentially not be around to collect.

However, keep in mind that, on average, a man who turns 65 these days is expected to live an additional 20.5 years. A 65-year-old woman is expected to live an additional 22.7 years. So odds are, if you're in at least average health and have parents who lived into their 80s and 90s, you can chalk one up in the delaying-benefits column.

2. Income needs
Naturally, delaying your benefit assumes you have income to bridge the gap between age 62 to full retirement age, or even up to age 70. If your savings are insufficient to pay for your income needs, then, by all means, collect early. But if you have sufficient income-producing assets or wages from continued employment, then strongly consider delaying your benefit. Keep in mind that you're still Medicare-eligible at age 65, regardless of what age you start collecting Social Security.

3. Spousal considerations
Benefit calculations become much more complex if you're married. If you take benefits early and receive a permanent reduction, your spouse's survivor benefit will also be permanently reduced, which could have a major effect on your spouse's income after you pass away. Some spousal claiming strategies include "file and suspend" and claiming a spousal benefit now and your own benefit later. Make sure you think through how your decision will affect your family members.

Foolish final thoughts
When to start receiving Social Security benefits is not a decision to be taken lightly. It shouldn't be based solely on what your brother-in-law or best friend is doing. Since everyone's situation is different, be sure to evaluate what's best for you and your loved ones in making this critical decision.

Making the right financial decisions today makes a world of difference in your golden years, but with most people chronically under-saving for retirement, it's clear not enough is being done. Don't make the same mistakes as the masses. Learn about The Shocking Can't-Miss Truth About Your Retirement. It won't cost you a thing, but don't wait, because your free report won't be available forever.

Goldman Sachs Group Inc. Bonds: How Much Risk, How Much Reward?

Commercial banks in the United States are required to prove to their regulators that their investments are in fact "investment grade" as defined by the regulators. In this note we analyze the current levels and past history of default probabilities for Goldman Sachs Group (GS). We compare those default probabilities to credit spreads on 1,162 bond trades in 134 different company bond issues on July 31, 2013. This trading volume made Goldman Sachs Group the second most heavily traded name on the day, trailing only General Electric (GE) Credit Corporation. Goldman Sachs Group has some of the lowest default probabilities of any firm analyzed in this series of credit notes to date. Trading volume in these 134 Goldman Sachs Group bonds on July 31 totaled $358.3 million, and the analysis in this note is based on those traded prices.

Assuming the recovery rate in the event of default would be the same on all bond issues, a sophisticated investor who has moved beyond legacy ratings seeks to maximize revenue per basis point of default risk from each incremental investment, subject to risk limits on macro-factor exposure on a fully default-adjusted basis. We analyze the maturities where the credit spread/default probability ratio is highest for Goldman Sachs Group. We also consider whether or not a reasonable investor would judge the firm to be "investment grade" under the June 2012 rules mandated by the Dodd-Frank Act of 2010.

Definition of Investment Grade

On June 13, 2012, the Office of the Comptroller of the Currency published the final rules defining whether a security is "investment grade," in accordance with Section 939A of the Dodd-Frank Act of 2010. The new rules delete reference to legacy credit ratings and replace them with default probabilities as explained here.

Term Structure of Default Probabilities

Maximizing the ratio of credit spread to matched maturity default probabilities requires that default probabilities be available a! t a wide range of maturities. The graph below shows the current default probabilities for Goldman Sachs Group ranging from one month to 10 years on an annualized basis. The default probabilities range from 0.00% at one month to 0.00% at 1 year and 0.04% at ten years. Note that the default probabilities at the 1 month and 1 year maturity are not literally zero -- they are reported as zero only because of rounding to two decimal places.

(click to enlarge)

We explain the source and methodology for the default probabilities below.

Summary of Recent Bond Trading Activity

The National Association of Securities Dealers launched the TRACE (Trade Reporting and Compliance Engine) in July 2002 in order to increase price transparency in the U.S. corporate debt market. The system captures information on secondary market transactions in publicly traded securities (investment grade, high yield and convertible corporate debt) representing all over-the-counter market activity in these bonds. TRACE data for Goldman Sachs Group included 1,162 trades in 134 fixed-rate non-callable bonds of the firm on July 31, 2013.

The graph below shows 5 different yield curves that are relevant to a risk and return analysis of Goldman Sachs Group bonds. These curves reflect the noise in the TRACE data, as some of the trades are small odd-lot trades. The lowest curve, in dark blue, is the yield to maturity on U.S. Treasury bonds, interpolated from the Federal Reserve H15 statistical release for that day, that matches the maturity of the traded bonds of Goldman Sachs Group. The second lowest curve, in the lighter blue, shows the yields that would prevail if investors shared the default probability views outlined above, assumed that recovery in the event of default would be zero, and demanded no liquidity premium above and beyond the default-adjusted risk-free yield. The third line from the bottom (in orange) graphs! the lowe! st yield reported by TRACE on that day on Goldman Sachs Group bonds. The fourth line from the bottom (in green) displays the average yield reported by TRACE on the same day. The highest yield is obviously the maximum yield in each Goldman Sachs Group issue recorded by TRACE.

The data makes it very clear that there is a very large liquidity premium built into the yields of Goldman Sachs Group above and beyond the "default-adjusted risk free curve" (the risk-free yield curve plus the matched maturity default probabilities for the firm). The credit spreads are volatile because the traded prices provided by TRACE are volatile, even on the same underlying bond on the same day.

(click to enlarge)

The high, low and average credit spreads at each maturity are graphed below. Credit spreads are gradually increasing with the maturity of the bonds, although the TRACE data shows that credit spreads vary considerably during the day, in part as a function of the amount of bonds bought or sold in a given trade.

(click to enlarge)

Using default probabilities in addition to credit spreads, we can analyze the number of basis points of credit spread per basis point of default risk at each maturity. This ratio of spread to default probability is shown in the following table for Goldman Sachs Group. At all maturities, the reward from holding the bonds of Goldman Sachs Group, relative to the matched maturity default probability, is at least 25 basis points of credit spread reward for every basis point of default risk incurred. The ratio of spread to default probability is literally "off the charts" at maturities under 2 years because of the near-zero default probabilities for Goldman Sachs Group at those maturities.

(click to enlarge)

(click to enlarge)

The credit spread to default probability ratios are shown in graphic form here, with the vertical axis capped at a ratio of 100 times:

(click to enlarge)

The Depository Trust & Clearing Corporation reports weekly on new credit default swap trading volume by reference name. For the week ended July 26, 2013 (the most recent week for which data is available), the credit default swap trading volume on Goldman Sachs Group showed 25 contracts trading with a notional principal of $191.8 million for the entire week. The next graph shows the weekly number of credit default swaps traded on Goldman Sachs Group in the 155 weeks ended June 28, 2013. Goldman Sachs Group ranked 21st of 1,144 reference names in contracts traded over this period:

(click to enlarge)

The table below summarizes the key statistics of credit default swap trading in Goldman Sachs Group during this three year period.

(click to enlarge)

On a cumulative basis, the default probabilities for Goldman Sachs Group range from 0.00% at 1 year (rounded to 2 decimal places) to 0.35% at 10 years, as shown in the following graph.

(click to enlarge)

Over the last decade, the 1 year and 5 year default probabilities for Goldman Sachs Group have varied as shown in the following graph. The one year default probability peaked at just under 0.35% and the 5 year default probability peaked at just under 0.25% during that period. This is an exceptional performance rel! ative to ! other securities firms that failed or were rescued during the credit crisis.

(click to enlarge)

The legacy credit ratings (those reported by credit rating agencies like McGraw-Hill (MHFI) unit Standard & Poor's and Moody's (MCO)) for Goldman Sachs Group have changed only three times during the decade.

The macro-economic factors driving the historical movements in the default probabilities of Goldman Sachs Group include the following factors of those listed by the Federal Reserve in its 2013 Comprehensive Capital Analysis and Review:

Real gross domestic product The consumer price indexThe 30 year fixed rate mortgage yieldThe Dow Jones Industrial indexThe VIX volatility indexHome price indicesCommercial real estate price indices3 international macro factors

These macro factors explain 85.3% of the variation in the default probability of Goldman Sachs Group, a high proportion.

Goldman Sachs Group can be compared with its peers in the same industry sector, as defined by Morgan Stanley and reported by Compustat. For the US diversified financials sector, Goldman Sachs Group has the following percentile ranking for its default probabilities among its peers at these maturities:

1 month 5th percentile

1 year 6th percentile

3 years 13th percentile

5 years 0th percentile

10 years 0th percentile

Goldman Sachs Group is the least risky of the 220 firms in the US diversified financials sector at 5 and 10 year maturities. A comparison of the legacy credit rating for Goldman Sachs Group with predicted ratings indicates that the statistically predicted rating is 1 ratings notch below the actual legacy rating assigned to the company.

Conclusions

Goldman Sachs was literally the only large U.S. securities firm that survived the credit crisis without (a) borrowing a very significant amount of money from the Federal Reserve and without (b) a near-deat! h experie! nce. A Kamakura Corporation study showed that Goldman's peak borrowings from the Fed during the crisis were $24.2 billion on October 15, 2008. Current short-term default risk is so close to zero that default probabilities are indistinguishable from zero when rounding to two decimal places at one month and one year maturities. The company currently offers more compensation in terms of credit spread per basis point than any other company yet reviewed in this series. Legacy credit ratings for Goldman Sachs Group are one notch higher than that which one would predict using the best available statistics and default probabilities. The main risk facing Goldman Sachs Group is the potential for a sudden failure of risk management, in spite of the firm's fine reputation in this regard. JPMorgan Chase (JPM) had the same such reputation before the London Whale trading losses were announced in 2012. At current default probability levels, we believe that a very strong majority of sophisticated analysts would rate Goldman Sachs Group investment grade by the Comptroller of the Currency definition.

Background on Default Probabilities Used

The Kamakura Risk Information Services version 5.0 Jarrow-Chava reduced form default probability model makes default predictions using a sophisticated combination of financial ratios, stock price history, and macro-economic factors. The version 5.0 model was estimated over the period from 1990 to 2008, and includes the insights of the worst part of the recent credit crisis. Kamakura default probabilities are based on 1.76 million observations and more than 2000 defaults. The term structure of default is constructed by using a related series of econometric relationships estimated on this data base. An overview of the full suite of related default probability models is available here.

General Background on Reduced Form Models

For a general introduction to reduced form credit models, Hilscher, Jarrow and van Deventer (2008) is a good place to begin. Hilscher and Wi! lson (201! 3) have shown that reduced form default probabilities are more accurate than legacy credit ratings by a substantial amount. Van Deventer (2012) explains the benefits and the process for replacing legacy credit ratings with reduced form default probabilities in the credit risk management process. The theoretical basis for reduced form credit models was established by Jarrow and Turnbull (1995) and extended by Jarrow (2001). Shumway (2001) was one of the first researchers to employ logistic regression to estimate reduced form default probabilities. Chava and Jarrow (2004) applied logistic regression to a monthly database of public firms. Campbell, Hilscher and Szilagyi (2008) demonstrated that the reduced form approach to default modeling was substantially more accurate than the Merton model of risky debt. Bharath and Shumway (2008), working completely independently, reached the same conclusions. A follow-on paper by Campbell, Hilscher and Szilagyi (2011) confirmed their earlier conclusions in a paper that was awarded the Markowitz Prize for best paper in the Journal of Investment Management by a judging panel that included Prof. Robert Merton.

Source: Goldman Sachs Group Inc. Bonds: How Much Risk, How Much Reward?

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. (More...)

Why BP Earnings Won't Gush Higher

BP (NYSE: BP  ) will release its quarterly report tomorrow, and investors remain uncertain whether the company will ever fully recover from the Gulf oil spill three years ago. The stock is nowhere near its levels from before the spill, and it's unclear when BP earnings will stop feeling the impact of one-time charges and asset writedowns.

On the surface, conditions in the energy industry would seem to favor BP, as oil prices remain high and new discoveries around the world are helping other oil giants keep their production levels up. BP has had its share of successes, but those wins haven't turned around investors' somewhat negative sentiment about the stock. Let's take an early look at what's been happening with BP over the past quarter and what we're likely to see in its quarterly report.

Stats on BP

Analyst EPS Estimate

$1.13

Change From Year-Ago EPS

(2.6%)

Revenue Estimate

$90.3 billion

Change From Year-Ago Revenue

(3.3%)

Earnings Beats in Past Four Quarters

3

Source: Yahoo! Finance, S&P Capital IQ.

When will BP earnings grow consistently?
Analysts have shown mixed beliefs about the future direction of BP earnings. In the past few months, they've lopped a dime per share from their June-quarter estimates, but they've raised their full-year 2013 estimates by nearly 5% and their 2014 consensus by more than 10%. The stock, though, hasn't made a big move, climbing just 5% since late April.

Three years on, the Gulf oil spill continues to weigh on BP. Last month, the company said that it had completed active cleanup activity in Florida, Alabama, and Mississippi, leaving only 84 miles of Louisiana coastline to finish cleaning up. With BP and other parties to the spill having spent roughly $20 billion in litigation and cleanup costs, the oil giant is eager to put the episode behind it once and for all.

BP has responded by continuing to sell off non-core assets to raise cash. In June, the company finalized a $2.4 billion sale of assets to Tesoro (NYSE: TSO  ) , which included a California refinery and a network of 800 retail gas stations. The move helps bolster Tesoro's presence on the West Coast, but for BP, the amount raised is only a fraction of what it will end up having spent in the wake of the Gulf spill.

But BP has done its best to focus on growth efforts elsewhere. In response to tax reform efforts that encouraged further investment in Alaska's North Slope, BP joined ExxonMobil (NYSE: XOM  ) and ConocoPhillips (NYSE: COP  ) in investing an additional $1 billion in the area over the next five years. The companies are also considering more wells in the Prudhoe Bay oilfield as well as streamlining transportation of oil southward, which could require even more capital expenditures. But as long as oil prices remain high, the benefits are worth the expense. In addition to Alaska, BP is also planning to invest in 40 major exploration and production projects through 2020, with 11 of them requiring $10 billion each in gross investment across regions including the North Sea, Angola, Azerbaijan, and the Gulf of Mexico.

In the BP earnings announcement, watch for the latest on the ongoing litigation over the Gulf oil spill. With a new trial scheduled for September as well as an outstanding verdict and a new fight about alleged mishandling of claims for compensation from those affected by the spill, BP still has billions at stake in resolving its legal woes successfully.

You know having energy-stock exposure is a smart move, but which stocks should you buy? We've got your answers here in our newly updated research report, "3 Stocks for $100 Oil". For FREE access to this special report, simply click here now.

Click here to add BP to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Best Biotech Stocks To Own For 2014

Big pharma isn't the first industry many investors envision when dreaming of the big profits to be made from health care stocks. While blockbuster drugs can propel the top big pharma companies to massive profits, these broad behemoths can't match the exciting growth potential and immediate investor return of an up-and-coming biotech firm breaking out into its own.

For dividend investors, however, big pharma's unmatched in health care. Offering the stability of a wide drug portfolio and sizable revenue, top pharmaceutical firms are enticing picks for income investors. Merck (NYSE: MRK  ) stock's 3.8% dividend yields stands out as one of the larger offerings in the sector, but is this the stock income investors can't afford to pass up?

Big payout, little flexibility
That 3.8% dividend with Merck stock is a big one: The yield tops many of its competitors in big pharma, but it does so at a cost. The dividend costs the firm an 87% dividend payout ratio, which is a tough pill to swallow for a company struggling with patent cliff-related revenue drops. There's little room for Merck to increase its dividend with that substantial of a payout.

Best Biotech Stocks To Own For 2014: NeoStem Inc (NBS)

NeoStem, Inc., incorporated on September 18, 1980, operates in cellular therapy industry. Cellular therapy addresses the process by which new cells are introduced into a tissue to prevent or treat disease, or regenerate damaged or aged tissue, and consists of a separate therapeutic technology platform in addition to pharmaceuticals, biologics and medical devices. The Company�� business model includes the development of novel cell therapy products, as well as operating a contract development and manufacturing organization (CDMO) providing services to others in the regenerative medicine industry. Progenitor Cell Therapy, LLC, the Company�� wholly owned subsidiary (PCT), is a CDMO in the cellular therapy industry. PCT has provided pre-clinical and clinical current Good Manufacturing Practice (cGMP) development and manufacturing services to over 100 clients advancing regenerative medicine product candidates through rigorous quality standards all the way through to human testing.

PCT has two cGMP, cell therapy research, development, and manufacturing facilities in New Jersey and California, serving the cell therapy community with integrated and regulatory compliant distribution capabilities. Its core competencies in the cellular therapy industry include manufacturing of cell therapy-based products, product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery and consulting services. The Company�� wholly-owned subsidiary, Amorcyte, LLC (Amorcyte) is developing its own cell therapy, AMR-001, for the treatment of cardiovascular disease. AMR-001 represents its clinically advanced therapeutic product candidate and enrollment for its Phase II PreSERVE clinical trial to investigate AMR-001's safety and efficacy in preserving heart function after a heart attack in a particular type of post Acute Myocardial Infarction (AMI) patients.

Through the Company�� subsidiary, Athelos Corporation (Athelos), the Company is collaborating w! ith Becton-Dickinson in early stage clinical development of a therapy utilizing T-cells, collaborating for autoimmune and inflammatory conditions, including but not limited to, graft vs. host disease, type 1 diabetes, steroid resistant asthma, lupus, multiple sclerosis and solid organ transplant rejection. The Company�� pre-clinical assets include its Very Small Embryonic Like (VSEL) Technology platform. The Company has basic research and development capabilities, manufacturing facilities on both the east and west coast of the United States.

Best Biotech Stocks To Own For 2014: Alnylam Pharmaceuticals Inc.(ALNY)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its core product programs under clinical or pre-clinical development include ALN-TTR, a Phase I clinical trial program for the treatment of transthyretin-mediated amyloidosis; ALN-APC, a Phase I clinical trial program for the treatment of hemophilia; ALN-PCS for the treatment of severe hypercholesterolemia; ALN-HPN, a pre-clinical development for the treatment of refractory anemia; and ALN-TMP, a pre-clinical development for the treatment of hemoglobinopathies, including beta-thalassemia and sickle cell anemia. The company?s partner-based programs comprise ALN-RSV01, a Phase II clinical trial program for the treatment of respiratory syncytial virus infection; ALN-VSP, a Phase I clinical trial completed program for the treatment of liver cancers; and ALN-HTT, a pre-clinical development for the treatment of Huntington?s disease. It has strategic alliances with Novartis Pharma AG; F. Hoffmann-La Roche Ltd; Takeda Pharmaceutical Company Limited; Isis Pharmaceuticals, Inc.; Medtronic Inc.; Kyowa Hakko Kirin Co., Ltd.; and Cubist Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Advisors' Opinion:
  • [By Glenn]

    A relatively new company, Alnylam Pharmaceuticals was founded in 2002, and their shares have shown steady growth since before January 2005. In early January 2012, the shares were worth about $30 and although there were some dips to less than $20 in October/November of this year, they ended up around $25 at the end of December. Alnylam develops RNAi therapies for respiratory diseases and Huntington's, among others and has a broad spectrum of products in its pipeline. This startup also has agreements with number of large companies including Novartis, Biogen an d Roche.

5 Best Warren Buffett Stocks To Own For 2014: InterMune Inc.(ITMN)

InterMune, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies in pulmonology and fibrotic diseases. In pulmonology, the company focuses on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. It markets pirfenidone, an orally active drug that inhibits the synthesis of TGF-beta under the Esbriet name in the European Union, as well as in a Phase III clinical trial in the United States. Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the Pirespa trade name. The company?s research programs focus on the discovery of small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. InterMune, Inc. was founded in 1998 and is headquartered in Brisbane, California.

Best Biotech Stocks To Own For 2014: Merck & Company Inc.(MRK)

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company?s Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, diabetes and obesity, infectious diseases, neurosciences and ophthalmology, oncology, vaccines, and women's health and endocrine. This segment also offers human health vaccines, such as preventive pediatric, adolescent, and adult vaccines. Its Animal Health segment discovers, develops, manufactures, and markets animal health products. This segment offers antibiotics, anti-inflammatory products, vaccines, products for the treatment of fertility disorders, and parasiticides for cattle, swine, horses, poultry, dogs, cats, salmons, and fish. The Consumer Care segment develops, manufac tures, and markets over-the-counter, foot care, and sun care products. Its over-the-counter product line includes non-drowsy antihistamines; treatment for occasional constipation; decongestant-free cold/flu medicine for people with high blood pressure; nasal decongestant spray; and treatment for frequent heartburn. This segment?s foot care products comprise topical antifungal, and foot and sneaker odor/wetness products; and sun care products include sun care lotions, sprays and dry oils; and sunburn relief products. The company serves drug wholesalers and retailers, hospitals, government agencies, physicians, physician distributors, veterinarians, animal producers, and managed health care providers, as well as food chain and mass merchandiser outlets in the United States and Canada. Merck & Co., Inc. was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.

Advisors' Opinion:
  • [By McWillams]

    Merck & Co. Inc. (NYSE: MRK : 31.91, 0.05) reported net income of $2.02 billion, or 65 cents per share in its fiscal 2011 second quarter, compared to net income of $752 million or 24 cents a year ago. Analysts had estimated earnings of 95 cents per share for the firm. The company's revenue rose 7 percent to $12.15 billion, better than analysts' forecast of $11.82 billion. Shares closed Thursday's trading at $34.93.

  • [By Smart Money]

    Forward P/E: 7.8.

     

    Five-year average forward P/E: 13.7.

    Discount to five-year average: 46%.

    The market's shift away from defensive stocks in sectors like pharmaceuticals and the Obama administration's proposed health care reforms are just a couple of issues weighing on Merck (MRK, news, msgs). Shares in the Whitehouse Station, N.J., company are also being hobbled by company-specific problems, such as disappointing sales of asthma treatment Singulair, its best-selling drug, as well as increased competition, patent expirations and a pipeline of drugs with poor prospects for Food and Drug Administration approval.

    Fortunately for Merck investors, the company's pending acquisition of Schering-Plough (SGP, news, msgs) should go a long way toward easing many of these problems, especially Merck's poor drug pipeline and its ability to remain competitive, says Morningstar analyst Damien Conover. "Merck greatly improved its long-term outlook by agreeing to acquire Schering-Plough," the analyst says.

50 Ways to Make Money at Home and Online

In this economy, making money online or part-time is an attractive proposition. It may seem intimidating at first, but don't worry -- you needn't be a design maven, crochet whiz or computer savant to earn a little extra on the side. Here are a few ways to turn what you currently have (stuff, skills, un-skills) into a little extra cash.

Plug your money leaks
Remember that while cutting back on expenses definitely helps your budget, the easiest way to save money is to make more. Still, we'll start off with some easy tips to stop bleeding money where it doesn't actually help much.

1. Refinance your mortgage
Interest rates are at an all time low, and many families are considering refinancing their home to save on monthly mortgage payments. Determine whether or not refinancing will save you money in the long term by following this guide.

2. Switch providers
Don't assume that your cable, phone and Internet bills are locked into a slow but inexorable climb. Taking the first provider that comes along is a great way to waste money that can be saved elsewhere. Once you reach the terms of your contract, get on the phone or in an office and negotiate your bill down – or at least get a few perks thrown in for free.

3. Get rid of cable
Cable can rack up a hefty bill over a year, especially when you keep pay-per-view, premium channel, and miscellaneous costs in mind. Opt for online providers like Netflix or Hulu Plus that let you stream shows directly onto your computer, mobile device, or TV.

Pro tip: Switch between 30-day trial periods of Netflix, Hulu Plus and Amazon Prime to get a full season of free watching.

4. Use credit cards with the best rewards
The best parts about credit cards are the perks and rewards that come with them. By using a card with shoddy rewards or cash back, you are doing yourself and your budget a disservice. Find a credit card that rewards wherever you spend the most, whether that's travel, gas, groceries, or (ohmigod) shoes -- the NerdWallet credit card tool makes personalized recommendations based on your own spending habits.

Pro tip: Use the calculator button to further customize your recommendation.

5. Invest wisely
You're never too young to start investing -- in fact, the time to have an aggressive (high risk, high reward) profile is when you're younger, and you don't plan to use the money for a couple decades. But there's no reason to pay top dollar for actively managed mutual funds. Despite the prestige and high fees, active funds outperform the market only 24% of the time. You're much better with an index fund, which has much lower fees and will probably get you a better return for your money. Stop paying to lose money!

6. Pay off your debt
You know how I just told you to invest? Paying off high-interest debt is the best investment you can make. It's virtually impossible to get a guaranteed 12% return on your investments -- unless you're getting rid of credit card debt. Get in the black first before you start looking for babies that talk about stocks. Check out our in-depth article on getting rid of debt for guidelines and ways to lower the interest on your debts.

7. Improve your credit score
This one is a no-brainer. There are multiple sites that let you check your credit score for free. After finding out where you stand, work on improving your score and contact your credit card, personal loan or other issuer to negotiate a lower interest rate.

8. Maximize your tax returns
A great way to boost your income part time happens during a particular part of the year. Take advantage of tax loopholes and exceptions to maximize your long-anticipated tax refund check.

9. Use rewards malls and cashback websites
Little-known fact: You can earn cash back for the money you spend online anyway, just by clicking through another website first. Your credit card probably has a rewards mall that offers 5% back or more on everything from Expedia to Macy's to Zales, and even if it doesn't, you can use straight-up cash-back sites like eBates or Upromise to get an automatic discount on online purchases.

10. Take advantage of rebates and coupons
Often, stores will advertise that they'll beat the lowest price offered by any other competitor. Many credit cards also give price match guarantees, paying the difference if the price drops below a certain amount after you've made the purchase. Check your card's fine print for details. Also, use coupon comparison tools to score quick deals without scouring the Internet or pawing through your neighbors' mail.

11. Consider a flexible savings account (FSA)
Your employer may offer an FSA, which allows you to cover medical expenses not paid by insurance tax-free. This can be anything from out-of-pocket costs to prescriptions to dependent coverage. Because it's tax-advantaged, you'll save up to 30% on medical expenses. Keep in mind, though, that you lose any funds you don't spend at the end of the year, so you need to know your budget well. If you have a high-deductible insurance plan, you can also contribute to a health savings account (HSA), which doesn't lose money at year-end.

Turn money into more money
You can set policies in place to grow your existing money further. Someone pretty smart once said that compounding is the greatest force in the universe. Keep in mind that both of the following techniques compound, meaning that taking action now will yield even larger benefits in the future.

12. Max out your IRA and 401(k)
Max out your 401(k) and IRA contributions every year -- not only will you receive a tax benefit, but given the low interest-rate environment, you're much better putting your money in the markets than sticking it into a savings account that doesn't beat inflation. A 22-year-old who invests $5,000 in an IRA and never invests again will enjoy $137,000 at retirement, compared to just $101,000 if she invested in a regular savings account. It doesn't matter how old you are -- unless you're paying off debt, the time to start saving for retirement is now.

13. Ask for a raise
Like we said, saving money is all well and good, but making more money is even better. Try negotiating for a raise -- even in a tough job economy, sitting down at the bargaining table with politeness, confidence and respect for yourself and the organization can have its benefits. Here's a great flow chart scripting a possible conversation -- preparation is key.

Pro tip: Catch your boss when she's in a good mood, but don't let her know you know she's in a good mood.

Mo' money, less clutter
Okay, let's be honest. Chances are, you have too much stuff. If you can identify high-value items and present them well, you can have a cleaner, more simple living space as well as money to spend on what you really want.

14. Have a garage sale
Wipe off the dust, clear out the storage closet, and set up a garage sale. Put some effort into presentation: Items lovingly arrayed on a plastic tablecloth will sell better than those chucked into a cardboard box. If you don't have enough clutter to warrant a garage sale on your own, rope a few other neighbors into a neighborhood-wide sale.

15. Value your antiques and collectibles
Dig into storage, sell off what is valuable and throw away the rest. Before you sell indiscriminately, get your collectibles, antiques, and heirlooms appraised. You may be selling rare valuable items at underpriced rates otherwise. After you've consulted with an expert, do a gut check by looking at eBay and similar websites to see if the price is reasonable.

16. Free and flea market flipping
Browse the "free" section on Craigslist or your local flea market for interesting items. Add your own special touches, restore the items, and resell for a profit. Buy interesting items both online and at your local flea market and restore them and resell for a profit. Flea Market Flips offers some great ideas for trash-to-treasure projects.

17. Sell your old mobile phone
Given the rate at which we churn through cell phones these days, you probably have an old cell phone lying around. Amazon offers gift cards for fully functional iPhones, while specialty sites like Gazelle and Swappa specialize in cash for cell phones.

18. Turn in printer cartridges
Many office supply stores, from Staples to Office Depot, will offer credits for empty printer cartridges. Not only is it good for your wallet, but it's good for the environment.

Take part in the share economy
If you have an extra anything, chances are there's someone who'd like to borrow it from you. As the so-called "share economy" grows, you have an increasing opportunity to get cash for your idling machines and empty space.

19. Rent out an underused parking spot
Parking spots can be a hot commodity, particularly in crowded cities. If you happen to be holding on to a coveted spot that you do not use all the time, put it up for rent on Craigslist. If your landlord or building offers you parking at a discount rate, consider seeing whether you can rent it out for a higher price -- assuming you're allowed to do so, of course.

20. Rent out a spare bedroom
If that extra guest bedroom in your midtown Manhattan walk-up is left unused, consider renting it out on Airbnb.com or other vacation rental sites. Make sure that everything is kosher with your rental agreement beforehand.

Pro tip: Even if you don't have a spare bedroom, chances are there's a college kid willing to pay for four walls, a door, an air mattress, a shower and more privacy than a hostel affords.

21. Rent out your car
Don't need your car on the weekend or during the day? Going on a trip? Services like Getaround and RelayRides let you rent out your car by the hour, while FlightCar arranges for an incoming traveler to rent your car rather than you having to pay for airport parking and letting it sit idle.

Turn talent into a paycheck

22. Crafty? Crochet away!
Have a penchant for crocheting, jewelry-making or embroidery? Sell your goods on Etsy.com. Etsy is the go-to site for artisans and simply impassioned folk selling home goods, paintings, and knickknacks.

Pro tip: Offer to make personalized products -- not only does it establish an emotional connection with the customer, but it often brings in more income.

23. Become a freelance writer
Sites like eHow and Livestrong will pay by the article for content on anything from business to tech to how to fart. While they say you'll need "professional experience" or a degree or certification, honestly, there's not much you'll be asked to write that a quick tour of Google can't make you an expert on.

24. Take up a skilled freelance gig
Websites like TaskRabbit, Odesk, and Craigslist offer opportunities to avid freelancers to pick up programming, design, and marketing jobs on the side. Working on a per-project basis lets your balance your side job with your current one. Sites like Freelancer.com can also offer a leg up.

25. Small-scale catering
Fancy yourself to be the next Iron Chef? Take those skills to the marketplace by setting up your own catering business that you can run out of your own kitchen on the weekend. Cook for dinners, birthday parties and friends' events; or just bake a bunch of cookies and stand outside the nearest bar at 2 a.m.

Heads up: Be careful to comply with food safety laws.

26. Become an online travel agent
Have a knack for finding the best deals on Expedia? Hawk your services as a low-cost alternative to full service travel agencies. You can earn a pretty commission by doing what you love.

27. Bartend
The great thing about nightlife is that it doesn't conflict with day life. Pick up late-night or weekend shifts to earn some extra income without sacrificing hours at your current job or studies.

28. Tutor
If you were an SAT whiz, there is a huge market for competitive parents and children looking for private tutors. Join a large company like Kaplan or Princeton Review, or tutor at your own schedule by going private.

29. Affiliate marketing
Do you write emails to your friends and family that actually get read? Are you blessed with a silver tongue, razor wit or keen eye for society? Write it up. Join an affiliate network (Amazon has a good one) to earn money whenever someone buys the product by going through your website or blog.

Turn lack of talent into a paycheck
You don't need to be a master craftsman, mixologist or Iron Chef to earn supplementary income. Here are some income boosters that don't require specialized skills.

30. Get paid to be a reviewer
Although you may fancy your Yelp Elite status, all those reviews really did not pay for much but a fancy badge and a few exclusive invites. Take your review skills to the marketplace and earn $1-$50 per review, depending on quality and technical knowledge required.

31. Sell your photos
Stock photo websites like iStockPhoto purchase images from everyday people. Even if you aren't Ansel Adams, the most commonly requested (and often overlooked) photos often include everyday images like stop signs, coffee cups and other everyday objects.

32. Resell food
True story: In college, Zappos founder Tony Hseih bought pizza from a parlor down the road and resold it at a profit in his college dorm room. His friend Alfred Lin would always buy two pizzas a night -- Hseih assumed he was just hungry. Turns out Lin was actually taking the pizzas upstairs and selling them at a slice for an even tidier profit. He later went on to become the Zappos COO.

Anyway, long story short, you can probably find lazy, hungry college kids and young adults outside of bars and in parks. They will happily buy pizza, beer and water by the unit and pay handsomely for the convenience.

Heads up: This is not exactly FDA-approved.

33. Referrals
Services as diverse as your cable company to your orthodontist will pay a nice little gift for both referrer and referred. Small businesses and companies just getting off the ground are often the most likely to give referral bonuses.

Pro tip: Your employer might well give referral bonuses, too, so scour your personal networks to see if you know a good fit for open positions.

34. Survey websites
Although those posters on the side of the road may overshoot how much you can potentially make by simply answering surveys online, generating a side income from online surveys is still possible and profitable.

35. You must be good at babysitting
Get yourself registered on a reliable sitter search website and get to work. Babysitters can make great pay and get some benefits like free Wi-Fi thrown in as well.

36. You aren't? Are you good at petsitting?
Most pet owners actually cannot afford a luxury weekend for their pet at the kennel. Price your rates competitively during your stint as a pet sitter and make sure your place allows for multiple pets. Many sites, such as Care.com, offer job boards for pet sitters and those looking for animal care.

37. Really? Still? Okay, how about house-sitting?
Even if you hate kids and animals, you can look for house-sitting gigs through personal referrals, Craigslist, or websites like Mind My House.

Pro tip: Double up the income by renting our your own domicile while house-sitting.

38. Participate in clinical research
Hospitals and academic medical centers live, breathe, and thrive on clinical trials. Most participants are paid a good amount of money for their dedication to research and the trial. Do not overload on this option, as being enrolled in too many trials with conflicting pharmaceutical regiments may lead to skewed results and a medically unhappy you.

39. Engage in market research
Market research is the bread and butter of advertisement agencies. Many large ad agencies will conduct large focus groups to better tailor their strategies. Contact a local or large market research firm and secure your spot in a future group.

40. Become a tour guide
If you happen to know a bit more history concerning the old town square than the average citizen (or if you can just Wikipedia it), consider running your own personal tour guide business. Walking tours are en vogue, and you can advertise your services on TripAdvisor for tourists looking for an insider's perspective.

41. Find seasonal work
Snow shoveling, amusement park work, holiday staffing and lifeguarding are all seasonal work options that are low commitment and can be done sparingly according to your schedule. You want flexibility, employers want flexibility -- it works.

42. Become a part-time care taker
With the baby boomer generation retiring, many older folk in your community will require the services of a caretaker to help them around the house and with chores. Make a side income at a job that helps you contribute to your local community.

43. Host a foreign exchange student
Hosting an exchange student can be a source of cultural, as well as material, enrichment. Check out the number of hosting sites online, or contact your local high school or college for international student programs.

44. Data entry
Pick up administrative and data entry jobs that can be done by telecommuting, on Craigslist, or at your college campus's career center.

45. Become an on-site manager or landlord
Earn a spot to live rent-free while making a side income as an on-site manager for apartment building owners that live outside of town.

46. Garden
Turn your passion for all things green into a side business by offering landscaping and gardening tutorials to fellow flower aficionados.

47. Donate plasma, sperm or blood
These three precious bodily liquids are always in demand, and you can often get paid for the service. Be careful, though: Only go with reputable organizations that won't leave you in an ice-filled bathtub minus a kidney.

Heads up: The Red Cross recommends waiting 28 days between plasma donations and 56 between blood donations, and not exceeding 13 plasma donations a year.

48. Become a mystery shopper
Yes, they really do exist. Market research firms and companies doing internal audits often want to see how their stores perform from a customer's perspective, so sign up to become their eyes and ears.

49. Micro-task
Services such as Amazon Mechanical Turk connect businesses with a cohort of individuals looking to make a little cash on the side (i.e., you), in order to crowdsource small tasks. You can walk away with a nice check or gift card for a few hours of work.

50. Join a car service
The taxicab industry used to be limited to a handful of licensed professionals. Now, companies like Sidecar, Lyft and Flightcar allow anyone with a license to perform the same functions as a taxi driver, but with greater flexibility, and sometimes better pay.

The Birth and Boom of the World's Largest Chip-Maker

On this day in economic and business history...

Gordon Moore and Robert Noyce were part of the founding team behind Fairchild Semiconductor (NYSE: FCS  ) in 1957. In 11 years, the two men would forge legendary hardware-engineering careers. They developed the first practical integrated circuits, created the most widely recognized "law" of computing power, and built the chips that helped man land on the moon. But after 11 years, the two chip makers left the plodding Fairchild behind for even greater ambitions. On July 18, 1968, they founded Intel (NASDAQ: INTC  ) , a company that would quickly and vastly eclipse their former employer.

The company will engage in research, development, adn [sic] manufacture and sales of integrated electronic structures to fulfill the needs of electronics systems manufacturers. This will include thin films, thick films, semiconductor devices, and other solid-state components used in hybrid and monolithic integrated structures.
-- First paragraph of Intel's three-paragraph business plan written by Gordon Moore.

Moore later told NPR that they left because "we got to the point that electronics were going into almost all consumer items, so we had the feeling that this was the basic technology of some kind of a revolution." An understatement, to be sure.

Originally called NM Electronics, after its co-founders' initials, the company soon renamed itself to the familiar brand "inside" most PCs after it purchased the rights to "Intel" from a hotel chain called Intelco. The name is simply a portmanteau of Integrated Electronics; the shortened form of "intelligence" was a bonus. In its first fiscal year, Intel recorded no sales and spent about $350,000 on research and development -- an amount Intel spent on R&D every 32 minutes during its 40th year in operation.

Intel's first two products, released in 1969, were memory chips, but Intel made its name in 1971 with the release of the world's first commercial central processing unit, or CPU. Intel went public shortly after it launched this groundbreaking product, and its shares, despite remaining well below their dot-com peaks, have still produced total returns (with dividends reinvested) of about 180,000% over the subsequent four decades. The company's IPO raised a paltry $6.8 million, but that was more than enough to build mountains.

Despite opening an early position in CPUs, Intel remained very much a memory-chip maker until the 1980s, when low-cost Japanese competition buzz-sawed its way through American memory-makers. Intel, unlike its peers, had recently opened a fallback position that would transform it into one of the most successful technology companies in history: the IBM (NYSE: IBM  ) PC, which had been built with off-the-shelf components -- including Intel's 8088 processor, an offshoot of the 8086 -- to get to market faster.

IBM's engineering decision to use Intel chips rather than its own in-house chips would have enormous repercussions for the computer industry. IBM's hardware became a blueprint, but every other company that reverse-engineered that blueprint had to use Intel's CPUs, as the entire system was locked into Intel architecture by design. Then-CEO Moore and Andy Grove, Intel's employee No. 3 and its CEO from 1987 to 1998, initially underestimated the phenomenal impact the PC would have on Intel's bottom line. One of their early assumptions, according to NPR, was that it was a rather trivial product but might be a good way for cooks to store recipes. However, they were smart enough to keep their chip designs proprietary and build them in-house.

The rest, as you know, is history. Intel rode the PC revolution and the dot-com bubble to one of the largest market capitalizations in American history. Near the top, it joined the Dow Jones Industrial Average (DJINDICES: ^DJI  ) , along with Microsoft, as representatives of a "new economy" made possible by the global adoption of a standard hardware-software pairing. In 2012, Gordon Moore reflected to Fortune on holding on to his Intel shares long past the point of their peak: "You win a few, you lose a few. On balance, I've come out OK." He does have a knack for understatements.

It's incredible how much our digital and technological lives are shaped by just a handful of companies. Find out "Who Will Win the War Between the 5 Biggest Tech Stocks" in The Motley Fool's latest free report, which details the knock-down, drag-out battle being waged by the five kings of tech. Click here to keep reading.

Smartphone Screen Size: What Will Apple Do Next?

The trend is unmistakable: Smartphone screens are getting larger and larger. Where will it all end?

That was one of the questions addressed recently at CE Week in New York City. According to Mashable, which hosted a panel on "The Battle Over Smartphone Screen Size," it's impossible to buy a top Google Android phone these days with a screen smaller than 4.7 inches. Apple (NASDAQ: AAPL  ) is still lagging in this area -- its iPhone 5 finally stepped up to a 4-inch display -- but there's speculation it will have to go larger as well.

Our roving reporter Rex Moore was in New York, and spoke with Mashable's Lance Ulanoff about Apple's next step in screen size for the iPhone and iPad.

Want to get in on the smartphone phenomenon? Truth be told, one company sits at the crossroads of smartphone technology as we know it. It's not your typical household name, either. In fact, you've probably never even heard of it! But it stands to reap massive profits NO MATTER WHO ultimately wins the smartphone war. To find out what it is, click here to access The Motley Fool's latest free report: "One Stock You Must Buy Before the iPhone-Android War Escalates Any Further..."

Investors Eye Fed for Further Clues on Interest Rates

federal reserve fomc meeting chairman ben bernanke bank interest rates bond buying stimulusManuel Balce Ceneta/APFederal Reserve Chairman Ben Bernanke WASHINGTON -- When the Federal Reserve offers its latest word on interest rates this week, few think it will telegraph the one thing investors have been most eager to know: When it will slow its bond purchases, which have kept long-term borrowing rates low. The Fed might choose to clarify a separate issue: When it may raise its key short-term rate. The Fed has kept that rate near zero since 2008. It's said it plans to keep it there at least as long as unemployment remains above 6.5 percent and the inflation outlook below 2.5 percent. Unemployment is now 7.6 percent; the inflation rate is roughly 1 percent. Chairman Ben Bernanke has stressed that the Fed could decide to keep its short-term rate ultra-low even after unemployment reaches 6.5 percent. Testifying to Congress this month, Bernanke noted that a key reason unemployment has declined is that many Americans have stopped looking for jobs. When people stop looking for work, they're no longer counted as unemployed. If that trend continues, Bernanke said that lower unemployment could mask a still-weak job market and that the Fed might feel short-term rates should stay at record lows. In the statement the Fed will issue when its two-day meeting ends Wednesday, it could specify an unemployment rate below 6.5 percent that would be needed before it might raise its benchmark short-term rate. It might also say that it won't raise that rate if inflation fell below a specific level. Investors would react to any such shift in the Fed's guidance. Financial markets have been pivoting for months on speculation that the Fed will or won't soon slow its $85-billion-a-month in Treasury and mortgage bond purchases. Those purchases have led more consumers and businesses to borrow, fueled a stock rally and supported an economy slowed by tax increases and federal spending cuts. The Fed has signaled that it might slow its bond buying as soon as September -- if the economy has strengthened as much as the Fed has forecast. If not, the Fed would likely maintain its stimulus. On Wednesday, the government will report how fast the economy grew in the April-June quarter. Most economists predict an annual rate of barely 1 percent -- far too weak to quickly reduce unemployment. Most think the growth is picking up in the second half of the year on the strength of a resurgent housing market, stronger auto sales, steady job gains and higher pay. Many economists think the key goal of the Fed's policy discussions Tuesday and Wednesday will be to stress that the Fed's actions in coming months will hinge on how the economy fares, not on any timetable. Some economists think the Fed will be mindful that the Dow Jones industrial average sank more than 500 points in two days after it met in June and Bernanke said the Fed would likely slow its bond-buying this year and end it next year because the economy was improving. "The Fed is going to try to calm things down," said Brian Bethune, an economics professor at Gordon College, in Wenham, Mass. Last month, in what was likely his last economic report to Congress, Bernanke said that even after the Fed has begun slowing its bond purchases, its policymaking will keep lending costs down. Besides keeping its short-term rate low, Bernanke stressed that the Fed will maintain its vast investment portfolio -- which exceeds $3.4 trillion -- to help keep long-term borrowing costs down. Some economists still think the Fed will start trimming its bond purchases at its Sept. 17-18 meeting. Unlike this week's meeting, the September meeting will be followed by a news conference in which Bernanke could explain the actions. Diane Swonk, chief economist at Mesirow Financial, said she believes September is a likely time for the Fed to scale back its bond buying. Yet she doubted it will do anything this week to signal that possibility.

"The less said right now, the better" for financial markets, Swonk said. David Jones, chief economist at DMJ Advisors, said he still thinks the Fed will start trimming its bond purchases gradually starting in September. But he thinks that date could slip if the economy doesn't strengthen over the next two months. Other economists think the Fed may prefer to wait until after September to trim its purchases to make sure the economy is sustaining its gains. The Fed's moves to reduce its bond purchases will likely occur just as it will be managing a transition to a new leader. Bernanke is widely expected to step down when his second four-year term as chairman ends Jan. 31. Vice Chair Janet Yellen is viewed as a leading candidate to replace Bernanke, though former Treasury Secretary Lawrence Summers and others have also been mentioned.

GM's 2014 Silverado Is No. 1

Ford (NYSE: F  ) has enjoyed years of success with the F-Series, which remain America's best-selling vehicles. That status is something General Motors (NYSE: GM  ) aims to change with the 2014 Silverado. In an industry that sees vehicle makeovers every two to three years, the Silverado is considered a dinosaur -- the last redesign was completed back in 2006. Yet there's no doubt that the 2014 Chevy Silverado will mark the No. 1 most important vehicle launch since the automaker went bankrupt. Here's what you need to know.

Just how important is the Silverado?
Now that it's mostly done dealing with the aftereffects of its $50 billion U.S. taxpayer-funded bailout, GM is spending capital to redesign its vehicle portfolio. It's been estimated that GM invested between $3 billion and $4 billion to develop these new trucks and engines. That's a lot of money invested that won't be evident from the trucks' outside appearance, as the design remains very similar. 

Source: General Motors Media Photos.

The money spent will, however, be evident from both an investing and consumer standpoint. GM is updating the interior with plenty of technology innovations, as well as upgrading the gas mileage with its line of EcoTec engines. For investors in particular, money put into revamping the plants where the trucks are built will help improve operating efficiencies and profits per vehicle. It's all part of the CEO's plan to clone its rival's "One Ford" strategy and raise operating margins in the U.S. to 10%.

Doing it right the first time
It's incredibly important for management not to rush this launch and to do it right the first time. Chevy's 2014 Silverado will have a year's head start before the next-generation F-150 is released and can use a surging pickup segment to win back lost market share. Here's what GM Global product development chief Mary Barra had to say about the launch:

"I'm very confident that everything's on track and moving forward. ... It's been the most rigorous process we've gone through to make sure we put a high-quality truck into the marketplace, day one. ... [The launch is] going to be shortly." 

The current models are estimated to generate up to $12,000 of profit per vehicle, but with the Silverado's old age, GM has to increase incentives to succeed against its competitors. Investors can expect margins and profits to improve with the new model.

Inventory
GM's management will have to carefully control the 2013 Silverado inventory, which spiked early this year. GM decided it won't increase pricing on the 2014 model, which is an aggressive move and will make selling old 2013 models more dependent on a major boost in incentives. In other words, GM could be stuck with less favorable options to move the old trucks off the dealer lots. Correctly timing the launch of the new model while winding down current inventories will be key to considering this launch a success.

Bottom line
GM's past management ran the company into the ground before the recession came along and finished the job. With a new crew running the ship, things have steadily improved, albeit more slowly than at rival Ford. By 2016, GM is going to replace, refresh, or redesign 90% of its vehicles, and proving to investors in the meantime that it can have successful vehicle launches could boost demand for its stock. GM wants to avoid ugly recalls shortly after the release of its vehicles -- as Ford encountered with the popular Fusion and Escape models -- and it certainly wants to avoid taking too long to get finished products to the lots, which is what happened with the Lincoln MKZ.

In short, this is the single most important launch for GM in the past 10 years. The world is watching, and as an investor, I hope GM does it right the first time.

Worried about GM?
Few companies lead to such strong feelings as General Motors. But ignoring emotions to make good investing decisions is hard. The Fool's premium GM research service can help, by telling you the truth about GM's growth potential in coming years. (Hint: It's even bigger than you might think. But it's not a sure thing, and we'll help you understand why.) It might help give you the courage to be greedy while others are still fearful, as well as a better understanding of the real risks facing General Motors. Just click here to get started now.

A New Era for Nuverra

If Heckmann changing its name wasn't confusing enough for investors, it appears as though Nuverra Environmental Solutions (NYSE: NES  ) will be venturing into a new business. The company just purchased a greenfield disposal facility that it will use for solid and oil waste from drilling operations. While the potential revenue for the company doesn't really move the needle for the company, the move is more important for the new image that Nuverra wants to reflect to its customers. 

Nuverra wants to be the one-stop shop for any waste-related business in the oil and gas industry, and this move is a step in that direction. In this video, Fool.com contributor Tyler Crowe looks at how this will fit into the company's business model and what investors in the company should watch for in the future.

No matter what niche product an oil services company may offer its clients, it's almost guaranteed that Halliburton is a main competitor. Halliburton, one of the top companies in the business, is one of the most complete oil services companies around, providing customers with a wide array of services. To access The Motley Fool's new premium research report on this industry stalwart, simply click here now and learn everything you need to know about how Halliburton is positioning itself both at home and abroad.

Riding the Highs and Lows of the Smartphone Market

Smartphones notched a whopping $239.9 billion in worldwide sales last year. That's pretty hefty number, but what's really interesting is that only 31% of the world's population is currently using smartphones -- leaving a huge amount of potential future growth.

For tech investors trying to figure out the smartphone market, there are two things you should keep in mind: smartphone prices are falling, but high-end devices can't be counted out.

It's not just about low-end smartphones
At the beginning of 2012, the average cost of a smartphone was $450, and now it's just $375, according to IDC. ABI Research expects shipments of smartphones under $250 will increase from 259 million this year to 788 million in 2018. In places like the U.S., the drop in prices comes as a result of smartphone saturation. Right now, the U.S. smartphone penetration has reached 51% to 55% saturation, and will hit 80% by 2017, according to eMarketer.

iPhone 5 with iOS 7. Source: Apple.

But mid-range and high-end smartphones aren't even close to being out of the game -- and Apple  (NASDAQ: AAPL  ) CEO Tim Cook definitely doesn't believe so. In a conference call last week he said, "I don't subscribe to the common view that the higher-end, if you will, of the smartphone market is at its peak." 

Depending on what analysts and research you read, Cook is either being overconfident or right on target. ABI Research seems to suggest the latter: "Mid- and high-cost smartphones will continue to play an important role for operators looking to seed their customer base with the most advanced smartphones." Apple has its own research to back up its confidence, considering it just sold 31.2 million iPhones in the fiscal third quarter of this year -- a record for the company.

It appears that Google (NASDAQ: GOOG  ) is siding with Apple's strategy. The company will spend $500 million to market its forthcoming mid-range to high-end Moto X phone -- more than Apple or Samsung's entire mobile marketing budget. Some think Google's launching the phone to set a high standard for phones using Android mobile operating system, but with a budget like that, it's more likely the company is getting serious about its role in the smartphone device segment. 

Motorola Mobility's new logo. Source: Motorola.

One thing the majority of the research and analysts agree on is that smartphone prices will continue to drop, and that as prices trend down it will eat into revenue and profits.

A recent report by Citigroup's Glen Yeung stated, "In order to achieve the steep rate of adoption associated with such expansion, we assert that smartphone ASPs will need to fall, further moderating industry revenue growth." Gartner Research echoed a similar sentiment recently: "The challenge in the smartphone market is also that, as penetration moves more and more to the mass market, price points are lowering and in most cases so do margins."

As smartphone prices are dropping, it's harder for larger companies to keep up with smaller vendors in emerging markets, which can put out phones with decent specifications for lower prices. That may be why Apple is reportedly going to launch a cheaper iPhone in the fall, and why Nokia (NYSE: NOK  ) is releasing the new Lumia 625 in Asia, Africa and Latin America.

Nokia Lumia 625. Source: Nokia.

As BGR pointed out, the new 625 will sell for about $300 greater than local vendor phones in Asia, but will come with specifications close to many Asian-made smartphones and will rely on its brand recognition to help sell the phone. While the 625 is on the higher end of low-priced smartphones, Nokia is also focusing on emerging markets with its Asha 501 smartphone -- a $99 device that started shipping in 90 countries last month.

While high-end phones are still selling well in some markets, the shift toward cheaper phones is definitely in full swing. Investors looking for future gains from tech companies would be wise to look into which companies have a solid global strategy for smartphone sales. Despite strong iPhone sales this past quarter, Apple still needs to work harder to succeed in emerging markets. Meanwhile, Nokia is firmly in emerging markets but has to prove to potential customers that it's worth considering among a growing number of smartphone options.

No smartphone maker is impervious to the changing mobile landscape, and I'd be cautious to assume that any device maker out there knows exactly how to tackle growing markets. As we've seen in Asia, smaller vendors are giving the big guns a run for their money -- and the same story may play out in other emerging markets as well.

As tech companies scramble to succeed in mobile, only one can emerge as the world dominator. Find out "Who Will Win the War Between the 5 Biggest Tech Stocks?" in The Motley Fool's latest free report, which details the knock-down, drag-out battle being waged by the five kings of tech. Click here to keep reading.

Top 5 Biotech Companies To Watch For 2014

It's a day that Arena Pharmaceuticals investors have long, long waited for: Obesity drug Belviq is now on the market.�

The company had a seemingly endless wait for DEA scheduling, ultimately receiving class 4 status.�In the meantime, competitor VIVUS got its obesity drug Qsymia approved and into patients' hands.�

In this video, health-care analyst David Williamson checks in on the obesity-drug wars, where things stand between Arena and VIVUS, and what Arena investors should look out for given some of Qsymia's initial challenges.

Who will win the obesity drug market?
Can VIVUS pick up its lagging sales and fend off the competition, or will Arena Pharmaceuticals reign supreme in the obesity space? If you're in the dark, grab copies of The Motley Fool's premium research reports on VIVUS and Arena Pharmaceuticals to stay up to date. Senior biotech analyst Brian Orelli gives investors the must-know information, including an in-depth look at the obesity market and reasons to buy and sell both stocks. Click now for an exclusive look at�Arena�and�VIVUS -- complete with a full year of free updates -- today.

Top 5 Biotech Companies To Watch For 2014: NeoStem Inc (NBS)

NeoStem, Inc., incorporated on September 18, 1980, operates in cellular therapy industry. Cellular therapy addresses the process by which new cells are introduced into a tissue to prevent or treat disease, or regenerate damaged or aged tissue, and consists of a separate therapeutic technology platform in addition to pharmaceuticals, biologics and medical devices. The Company�� business model includes the development of novel cell therapy products, as well as operating a contract development and manufacturing organization (CDMO) providing services to others in the regenerative medicine industry. Progenitor Cell Therapy, LLC, the Company�� wholly owned subsidiary (PCT), is a CDMO in the cellular therapy industry. PCT has provided pre-clinical and clinical current Good Manufacturing Practice (cGMP) development and manufacturing services to over 100 clients advancing regenerative medicine product candidates through rigorous quality standards all the way through to human testing.

PCT has two cGMP, cell therapy research, development, and manufacturing facilities in New Jersey and California, serving the cell therapy community with integrated and regulatory compliant distribution capabilities. Its core competencies in the cellular therapy industry include manufacturing of cell therapy-based products, product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery and consulting services. The Company�� wholly-owned subsidiary, Amorcyte, LLC (Amorcyte) is developing its own cell therapy, AMR-001, for the treatment of cardiovascular disease. AMR-001 represents its clinically advanced therapeutic product candidate and enrollment for its Phase II PreSERVE clinical trial to investigate AMR-001's safety and efficacy in preserving heart function after a heart attack in a particular type of post Acute Myocardial Infarction (AMI) patients.

Through the Company�� subsidiary, Athelos Corporation (Athelos), the Company is collaborating w! ith Becton-Dickinson in early stage clinical development of a therapy utilizing T-cells, collaborating for autoimmune and inflammatory conditions, including but not limited to, graft vs. host disease, type 1 diabetes, steroid resistant asthma, lupus, multiple sclerosis and solid organ transplant rejection. The Company�� pre-clinical assets include its Very Small Embryonic Like (VSEL) Technology platform. The Company has basic research and development capabilities, manufacturing facilities on both the east and west coast of the United States.

Top 5 Biotech Companies To Watch For 2014: (DYMTF)

Dynamotive Energy Systems Corporation engages in the development and commercialization of energy solutions for biomass-to-liquid fuel conversion based on its fast pyrolysis technology. The company?s fast pyrolysis technology uses biomass or biomass waste feedstock to produce BioOil as a fuel and char. BioOil is a renewable fuel, which could be replaced with natural gas, diesel, and other fossil fuels to produce power, mechanical energy, and heat in industrial boilers, fuel gas turbines, and fuel reciprocating engines. The company has a strategic alliance with Tecna S.A. of Argentina to develop commercial energy systems based on Dynamotive?s pyrolysis technology in Latin America and other markets on a non-exclusive basis. It has operations in Canada, the United States, Argentina, and the United Kingdom. The company was formerly known as Dynamotive Technologies Corporation and changed its name to Dynamotive Energy Systems Corporation in June 2001. The company was founded i n 1991 and is headquartered in Richmond, Canada.

Advisors' Opinion:
  • [By Paul]

    Although Dynamotive Energy Systems stock has lost value in 2012, so did a lot of green biotech and biofuel companies, and it has held its own since September, hovering around the $0.25 mark. The bio-oil company continues to grow and signed a new agreement, for project development in China, on December 1, 2012, generating a burst of excitement and growth for DYMTF shares.

Best Stocks To Invest In 2014: Organovo Holdings Inc (ONVO)

Organovo Holdings, Inc. (Organovo), formerly Real Estate Restoration & Rental, Inc., incorporated in 2007, is a development-stage company. The Company has developed and is commercializing a platform technology for the generation of three-dimensional (3D) human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. On December 28, 2011, Real Estate Restoration and Rental, Inc.�� (RERR) entered into an Agreement and Plan of Merger, pursuant to which RERR merged with its, wholly owned subsidiary, Organovo (Merger Sub). On February 8, 2012, the Company merged with and into Organovo Acquisition Corp. (Acquisition Corp.), a wholly owned subsidiary of Organovo, with the Company surviving the merger as a wholly owned subsidiary of Organovo Holdings (the Merger). As a result of the Merger, Organovo acquired the business of Organovo, Inc.

The Company has collaborative research agreements with Pfizer, Inc. (Pfizer) and United Therapeutic Corporation (Unither). As of March 31, 2012, it has five federal grants, including Small Business Innovation Research grants and developed the NovoGen MMX Bioprinter (its first-generation 3D bioprinter). The Company is engaged in the development of specific 3D human tissues to aid Pfizer in discovery of therapies in two areas of interest. In addition, in October 2011, it entered into a research agreement with Unither to establish and conduct a research program to discover treatments for pulmonary hypertension using its NovoGen MMX Bioprinter technology. Additionally, under the research agreement with Unither, the Company granted Unither an option to acquire from the Company a worldwide, royalty-bearing license in certain intellectual property created under the research agreement solely for use in the treatment or prevention of pulmonary hypertension and all other lung diseases.

The Company�� NovoGen MMX Bioprinter is an automate! d device that enables the fabrication of three-dimensional (3D) living tissues comprised of mammalian cells. A custom graphic user interface (GUI) facilitates the 3D design and execution of scripts that direct precision movement of the dispensing heads to deposit cellular building blocks (bio-ink) or supporting hydrogel. The Company is using a third party manufacturer, Invetech Pty., of Melbourne, Australia, to manufacture its NovoGen MMX Bioprinter. Its bioprinting technology and surrounding intellectual property and commercial rights serve as a platform for product generation across multiple markets that employ cell- and tissue-based products and services.

The Company competes with Organogenesis, Advanced BioHealing, Tengion, Genzyme, HumaCyte and Cytograft Tissue Engineering.

Top 5 Biotech Companies To Watch For 2014: Scancell Holdings PLC (SCLP)

Scancell Holdings PLC is a United Kingdom-based company. The Company�� principal activity of the consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. In April 2012, the Company completed recruitment to the Phase 1 clinical trial of SCIBI. In May 2012, the Company commenced recruitment and treatment of the first patient in the second part of it Phase 1/2 clinical trial of SCIBI. The Phase 2 part of the trial is conducted in five United Kingdom centers in Nottingham, Manchester, Newcastle, Leeds, and Southampton. On August 15, 2012, the Company announced the development of a platform technology, Moditope.

Top 5 Biotech Companies To Watch For 2014: Gentium SpA(GENT)

Gentium S.p.A., a biopharmaceutical company, focuses on the development and manufacture of its primary product candidate, defibrotide, an investigational drug based on a mixture of single-stranded and double-stranded DNA extracted from pig intestines. It develops defibrotide for the treatment and prevention of hepatic veno-occlusive disease (VOD), a condition that occurs when veins in the liver are blocked as a result of cancer treatments, such as chemotherapy or radiation, that are administered prior to stem cell transplantation. The company has completed a Phase III clinical trial of defibrotide for the treatment of severe VOD in the United States, Canada, and Israel; and a Phase II/III pediatric trial in Europe for the prevention of VOD. It also offers sulglicotide that is developed from swine duodenum, and has ulcer healing and gastrointestinal protective properties in South Korea; and urokinase, which is made from human urine to treat various vascular disorders, such as deep vein thrombosis and pulmonary embolisms. The company was formerly known as Pharma Research S.r.L. and changed its name to Gentium S.p.A. in July 2001. Gentium S.p.A. was founded in 1993 and is headquartered in Villa Guardia, Italy.

Advisors' Opinion:
  • [By Roger]

    Gentium is considered one of the best biotechnology stocks on the market, and offers a ROE that is terrific. The stock has been rebounding and while not at the 52 week high again yet it is quickly gaining.

Why American Capital Mortgage Is Ready to Rebound

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, mortgage REIT American Capital Mortgage Investment (NASDAQ: MTGE  ) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at MTGE and see what CAPS investors are saying about the stock right now.

MTGE facts

Headquarters (founded)

Bethesda, Md. (2011)

Market Cap

$1.1 billion

Industry

Mortgage REITs

Trailing-12-Month Revenue

$222.4 million

Management

Chairman / CEO Malon Wilkus
President / Chief Investment Officer Gary Kain

Trailing-12-Month Normalized Net Income Margin

57.2%

Cash / Debt

$1.9 billion / $7.8 billion

Dividend Yield

17.4%

Competitors

Annaly Capital Management 
Capstead Mortgage 
MFA Financial

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 98% of the 89 members who have rated MTGE believe the stock will outperform the S&P 500 going forward.

Just last week, one of those Fools, All-Star fearandgreed2005, tapped MTGE as a particularly attractive income opportunity:

Stock already beaten down in anticipation of rising interest rates. Huge [dividend yield] of 17% and capital appreciation after rates stabilize will cause stock to outperform. Rising long term rates and low short term rates will be positive for earnings. Solid management team will be able to steer the company through the present short-term turmoil.

Many investors are terrified about investing in big banking stocks after the crash, but the sector has one notable stand-out. In a sea of mismanaged and dangerous peers, it rises above as "The Only Big Bank Built to Last." You can uncover the top pick that Warren Buffett loves in The Motley Fool's new report. It's free, so click here to access it now.

Green Mountain: Starbucks Deal Hides Poor Report

After the bell on Wednesday, coffee giant Green Mountain Coffee Roasters (GMCR) released its fiscal second quarter results. Q2 was extremely mixed, with the company missing revenue estimates, but blowing out earnings estimates. The company also issued terrible Q3 revenue guidance, and lowered its full year revenue forecast. On the heels of the earnings beat in Q2, they raised their full year earnings forecast and cash flow guidance. However, the company also slashed its capital expenditures forecast again. Aside from the quarterly report, the company announced an extended partnership with Starbucks (SBUX). Today, I'll break down the results and see where Green Mountain goes from here. For those that missed it, here was my earnings preview for the name.

Second Quarter results:

For the quarter, Green Mountain reported revenues of $1.005 billion. This represented 13.53% growth over the prior year period. However, the company rounded this growth to the nearest percent, and because it was over 13.5%, they showed 14% growth. While mathematically this is acceptable, it doesn't tell the whole story. When Green Mountain gave guidance at their Q1 report, they guided to a sales growth range of 14% to 18%. Looking at 14%, it looks like they hit the bottom end of their range, which they didn't. Additionally, analysts were looking for 15.8% growth, a little more than $1.02 billion, so Green Mountain missed that number by $20 million. Don't forget, analysts were expecting 20.2% growth going into the Q1 report. Green Mountain lowered the bar, and still missed terribly. This was not an impressive revenue quarter.

On the margin side, Green Mountain improved gross margins by 595 basis points. The following table, taken from their Q2 report, shows how this was achieved.

(click to enlarge)

I will always give a company credit where it is due, and this was ! an extremely large jump in gross margins. The question going forward will be is it sustainable? Coffee prices will not decline forever, and some of the lower expenses they described can only go so low. Green Mountain did well in terms of margins, and their three primary margin categories over the past few years are below.

On the operating side, Green Mountain reported an increase in operating expenses of 24.23%, primarily driven by a 49.5% increase in general and administrative costs. Further down the income statement, the total of "other income items" went from a loss of $3.872 million to a loss of $6.231 million. This was partially offset by a lower tax rate at 35.61%, as opposed to 36.00% in the year ago period. As well as Green Mountain did on the gross margin side, the rest of the income statement hurt a bit. Their success did not flow down all the way.

On an earnings per share front, the company came in at $0.87 on a GAAP basis, four cents of which was helped by a lower share count due to the buyback. On a non-GAAP basis, which is what analysts use, Green Mountain came in at $0.93, which crushed analyst forecasts for $0.73.

Overall, this report reminds me of the past couple of years for Green Mountain. The company was light on sales, but had low enough expenses to fuel a huge earnings per share beat. Margin improvement was great, but it's not a good sign when you guide to 14% to 18% revenue growth, and you come in at 13.53%. That's a huge miss.

Another slashing of capex numbers:

Before I get to the rest of the company's guidance, which was poor, I want to briefly look at capital expenditures. Green Mountain's free cash flow numbers are calculated by subtracting capital expenditures for fixed assets from net cash provided by operating activities. The following is a recent history of Green Mountain's capex plans, spanning back about a ! year and ! a half.

When the company reported third-quarter results in 2011, it provided the following guidance for fiscal 2012:

Capital expenditures for fiscal 2012 in the range of $650 million to $720 million. In addition, as the Company secures new production facilities for future growth it may incur additional capital expenditures in the range of $50 million to $60 million in fiscal 2012.

When the company reported fourth-quarter results in 2011, the guidance changed to the following:

For fiscal 2012, we currently expect to invest between $630.0 million to $700.0 million in capital expenditures to support the Company's future growth.

The company did not revise its Capex guidance after first quarter results, but when it reported second-quarter results, it took down the forecast again:

Capital expenditures in the range of $525 million to $575 million.

When the company reported third-quarter results, it again took down the forecast for 2012 Capex.

Capital expenditures in the range of $475 to $525 million, down from prior estimates of $525 to $575 million.

When Green Mountain actually reported Q4, they reported free cash flow of $76.7 million and net cash provided by operating activities of $477.8 million. That means that capex was $401.1 million. So they initially guided to $700 million to $780 million in their prior fiscal year, and actually only put $401 million back into the business. That's why their free cash flow numbers looked so good.

That gets us to this fiscal year. At that Q4 report above, the company established the following capex and free cash flow guidance for this current fiscal year.

Free cash flow in a range of $100 million to $150 million. Capital expenditures in the range of $380 to $430 million.

So in Q1 they reported massive free cash flow of $254 million, and the following guidance.

Free cash flow in a range of $100 million to $150 million. Capital expenditures in the range of $350 to $400 million.

Since they ! lowered t! heir capex forecast by $30 million, you might have thought that they would have increased their free cash flow forecast? Nope, they didn't do it, they just said they expected to come in at the higher end. Well, in Q2 they had free cash flow of $202 million, giving a total of $456 million for the first half of the year.

Because they need to build inventory in the second half of the fiscal year, free cash flow actually goes negative in Q3 and Q4, which they tell us. That's fine, and no big deal. But here was their new guidance after this latest guidance after the Q2 report.

Free cash flow in a range of $300 million to $400 million. Capital expenditures in a range of $275 million to $325 million.

So the new forecast represents an increase of $200 million to $250 million. However, they cut capex guidance by $30 million last quarter, and another $75 million this quarter! Here's what they said after last quarter's Q1 call:

This revised capex represents approximately 8% of 2013 forecasted sales, down from 10% of sales in 2012 and 11% of sales in 2011.

Based on the new midpoints of their guidance, including the revenue guidance I'll get to in the next section, they are now expecting to invest just about 6.9% of sales. Again, this company is boosting its free cash flow numbers by cutting capital expenditures. Is this good for the long-term health of the business? That remains to be seen.

The rest of the guidance:

I would have been fine with the capex cut and free cash flow numbers had the company issued decent guidance, but they didn't!

For the full fiscal year, the company gave the following guidance:

Net sales growth in the range of 11% to 14% over fiscal year 2012.On a comparable basis, excluding the 53rd week of fiscal year 2012 which contributed $90 million in net sales in the Company's fourth quarter fiscal 2012, the Company's net sales growth outlook equates to growth in a range of 14% to 17%.On a comparable basis, the Company's expected fiscal 2013 reven! ue growth! rate is being driven by a 20% increase in the Company's core single serve business, offset by a 5% decline in its traditional coffee business, comprised of bagged coffee, fractional packs and office coffee services. As the entire coffee category's shift to Keurig® single serve continues, the Company's traditional coffee business will likewise continue to be adversely impacted.The Company continues to be comfortable with its longer-term outlook of annual net sales growth of 15% to 20%.Non-GAAP earnings per diluted share of $3.05 to $3.15, representing a growth rate of 27% to 31% over the $2.40 earnings per diluted share in fiscal 2012 (excluding the amortization of identifiable intangibles related to the Company's acquisitions; any acquisition-related transaction expenses; and legal and accounting expenses related to the SEC inquiry and the Company's pending securities and stockholder derivative class action litigation).On a comparable basis, excluding the 53rd week of fiscal year 2012 which contributed $0.07 in non-GAAP earnings per diluted share in the Company's fourth quarter of fiscal 2012, the Company's non-GAAP earnings per diluted share guidance equates to growth in a range of 31% to 35%.The Company's fiscal year 2013 non-GAAP earnings per diluted share estimate includes the impact of shares repurchased prior to March 30, 2013 as part of its previously announced share repurchase program, but excludes any impact from potential future Company share repurchases.Cash flow and capex guidance as detailed above.

That seemed like a mouthful, didn't it? Of course it was, because by stuffing that much information, you may have missed the key point. The company significantly reduced its revenue guidance. Prior guidance was for net sales growth of 15% to 20%, but now they are calling for just 11% to 14%. That's a huge takedown! They threw in that statement about the extra week to make the growth look better, and yes, on a 52-week to 52-week period, it will be. But in previous reports, they never gave that! extra ti! dbit. They are just doing it here to "hide" their huge negative revision. They also claim it is due to a decrease in sales of bagged coffee as they move to more single serve. But still, it does not matter to me. They are warning on revenues.

Additionally, the earnings forecast was boosted, which makes sense on the heels of the huge Q2 beat, plus the lower share count. Analysts were looking for $2.84 in earnings, so they will definitely have to raise their forecasts there. Overall, the revenue midpoint reduction means they are lowering their forecast by about $193 million. For a company that was expecting a midpoint of $4.535 billion, almost $200 million is a big deal.

But wait, there's more! Here's the company's guidance for fiscal Q3, which is the quarter we are currently in.

Net sales growth in the range of 11% to 15% over the third quarter of fiscal year 2012.Non-GAAP earnings per diluted share in a range of $0.71 to $0.78, an increase of 37% to 50% over the prior year period (excluding the amortization of identifiable intangibles related to the Company's acquisitions; and, legal and accounting expenses related to the SEC inquiry and the Company's pending securities and stockholder derivative class action litigation).The Company's non-GAAP earnings per diluted share estimate includes the impact of shares repurchased prior to March 30, 2013 as part of its previously announced share repurchase program, but excludes any impact from potential future Company share repurchases.

Now the earnings forecast is definitely great. Analysts were expecting $0.65, so the guidance is well above. However, if you factor in the share buybacks plus the huge rises in margins that they expect to carry through into Q3, I don't know if the forecast is that impressive. If analysts had known about this huge margin expansion, I think that their estimates would have been much higher.

But here's the real key, and it is revenues again. Analysts were expecting $1.02 billion for Q3, growth of 17.4%. The high e! nd of Gre! en Mountain's forecast didn't come anywhere near that. Green Mountain issued terrible revenue guidance for Q2, and they missed that completely. Q3 revenue guidance is even worse. The company is experiencing a much faster than expected revenue slowdown.

Balance Sheet / Cash Flow Highlights:

The company's balance sheet improved in Q2, thanks to that large earnings beat and help from free cash flow. Here's a summary table of some key financial ratios. Dollar values in thousands.

But the important part here is what's behind the numbers, rather than the numbers themselves. The company's cash position jumped because cash from operating activities was much higher and capex was lower, offset by the stock repurchases.

So let's look at the numbers behind the numbers. Through the first six months of the fiscal year, the company had cash flow from operating activities of $604.685 million. That was much higher than the $370.156 million in the year ago period (six months), a rise of about $234.5 million. But why did it rise so much? Here's the key points:

Net income rose by $42.57 million.Depreciation rose by $32 million.Last year's period included a $28.9 million gain on the sale of a subsidiary. This hurts cash flow, and is a subtraction to cash flow from operating activities.Inventory depletion was a $105 million add-back.Accounts payable and other expenses provided $3.7 million in cash this period, took away $17.5 million last year.

The net income rising was a good thing, and I'll give them credit for that. There are also many other items I did not detail, so please look at the whole cash flow statement to get the line by line data.

But here's my takeaway. The company's cash flow improved by almost $235 million. Of that, there was a close to $29 million sale gain last year that hurt cash flow in that period. Also, there was a $105 million add t! o cash fl! ow for inventories above last year's period. When your inventories go from say $100 million to $80 million, that's a $20 million add to cash. Green Mountain depleted their inventories by an extra $105 million in the first 6 months of this year. Why did they do that? One reason is that they reduced their sales forecast! When you reduce your sales forecast by $200 million, you don't need as much inventory! So they didn't replenish as much. Also, another $21 million "improvement" was from them letting accounts payable and other current liabilities rise, instead of paying them back.

On the face of it, the rise in cash flow from operating activities looks tremendous. But when you dig into the numbers, there isn't a ton to like here. I'll give them some credit for improvement, but to give them credit for all $235 million, or maybe even half of that, is wrong.

Expanded Starbucks deal:

Despite all of the negativity I've detailed, Green Mountain shares rallied strongly in the after hours session. That was most likely due to a new deal with Starbucks announced along with the quarterly results. The deal is for a minimum of five years, and details are found below.

The new, minimum five-year agreement announced today is a global single-serve coffee industry game changer. Under the new agreement, Starbucks will add brands and varietals to the already robust Starbucks® K-Cup® and Vue® pack portfolio of offerings for Keurig® single cup brewers, ultimately tripling the number of Starbucks® products and adding brands offered on the Keurig® platform. New brands will include Seattle's Best Coffee®, Torrefazione Italia® coffee, Teavana® Teas, and Starbucks® Cocoa. The new agreement reinforces Starbucks position as the exclusive licensed super premium coffee brand on the Keurig® K-Cup® and Vue® platforms, and further extends the Keurig® system's position as the exclusive low-pressure single cup brewing system for fresh-brewed Starbucks® coffee, Tazo® tea and the aforementioned Starbuck! s brands.! Financial terms of the agreement were not disclosed.

It certainly seems that bulls are looking at the longer-term picture here, and that makes sense to a point. Green Mountain's relationship with Starbucks has always been in question, and has always been one of the clouds hanging over Green Mountain's head. They said on the conference call that the deal started once signed, so the weak guidance is even more disappointing given the partnership.

Final Thoughts / Recommendation:

In the after-hours session, Green Mountain shares rallied $9.57 to $69.05, a gain of 16.09%. More than 2.9 million shares traded in the after-hours session, after 6 million shares during the day. I'm sure that some of this rally was due to short covering, with more than 32 million shares short, almost 20% of the outstanding count, as of the latest update from NASDAQ. More shorts could cover Thursday.

Now I think Green Mountain's rise will probably continue a bit as short sellers are forced to cover, and bulls focus on the long-term aspect of the Starbucks deal. However, I think Green Mountain returns to the short candidate list with this report. That doesn't mean I am necessarily recommending you short it right away. In addition to the poor Q2 revenue number, the revenue guidance takedown, and slashing of capex, there is another argument to be made.

Let's go back to August 2012. Green Mountain announced a stock buyback at its earnings report, which helped the stock recover from a 52-week low around $15.25 in the after-hours session after reporting that quarter. We are now at $68.00. That is a tremendous rally. But here's the issue. The company has now slashed revenue guidance twice. Going into that Q4 report, analysts were expecting $4.72 billion in revenues this fiscal year, ending in September. At that point, Green Mountain guidance, using their current guidance for both fiscal years, was $4.39 billion to $4.58 billion. That was at the Q3 report, and thanks to a huge Q4 number, their forecast for th! is year w! as "technically raised" because the number for the previous fiscal year was higher. That put the new range at $4.44 billion to $4.63 billion. Going into this quarterly report, analysts were expecting $4.47 billion, the low end of this range. Given the new guidance, Green Mountain is looking for revenues of $4.28 billion to $4.40 billion. So now, we are even lower than the original range.

So what's going on with Green Mountain? Two years ago, the company grew revenues by 95.4%. In their prior fiscal year, which had an extra week, they grew by 45.6%. Their guidance for this year is just 11% to 14% net growth, or 14% to 17% growth excluding the extra week. Non-GAAP earnings per share two fiscal years ago were $1.64, and this year is expected to be almost twice that. But two years ago today, this stock traded for $76.50. Despite two years of explosive revenue and earnings growth, the stock is actually down, because that growth has tremendously slowed. Green Mountain expects that growth to pick back up over the long-term, which probably could occur when they expand further internationally. This Starbucks partnership could be the start of that.

So why do I think Green Mountain is a short candidate? Well, I think that this stock will pop on the news, but this quarterly report and guidance was terrible to be honest. The growth slowdown is happening even faster than expected, and the company is not investing in their business. Cash flow numbers aren't what they seem, and the stock is being propped up by the buyback and stock markets rallying to new highs. When the music stops, will this company have a chair?

I consider this name as a short candidate if this post-earnings rally is just too much. I think as this report is fully digested, I think the stock will pull back, especially if we see $75 or $80 in the short-term. Remember, this stock has recently gone from $15 to $68, and they actually lowered their revenue guidance even further. Green Mountain certainly had more upside like I said it wou! ld, but I! think further gains could be limited. In early 2012, Green Mountain went from the low $50s to $70 on a good earnings report. At their next earnings report, the stock was in the mid $20s, and fell another $10 from there. I don't think this stock will plunge like that again, but I don't think this massive rally will continue much higher.

Disclosure: I have no positions in any stocks mentioned, but may initiate a short position in GMCR over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. (More...)

Additional disclosure: Investors are always reminded that before making any investment, you should do your own proper due diligence on any name directly or indirectly mentioned in this article. Investors should also consider seeking advice from a broker or financial adviser before making any investment decisions. Any material in this article should be considered general information, and not relied on as a formal investment recommendation.